Furthermore, a unique subset of tumor-reactive cells, identified by coexpression of CD39, CD103, and CD8 can be expanded by PD-1i or anti-OX40 treatment in patients with cancer (13, 14). The gene discussed is CD8A; the disease is neoplasm.